[1]刘廷胜.低分子肝素结合瑞舒伐他汀与醋酸泼尼松对肾病综合征患者肾功能及炎症因子的影响[J].医学信息,2020,33(08):158-160.[doi:10.3969/j.issn.1006-1959.2020.08.052]
　LIU Ting-sheng.Effect of Low Molecular Weight Heparin Combined with Rosuvastatin and Prednisone Acetate in the Treatment of Patients with Nephrotic Syndrome[J].Medical Information,2020,33(08):158-160.[doi:10.3969/j.issn.1006-1959.2020.08.052]
点击复制

低分子肝素结合瑞舒伐他汀与醋酸泼尼松对肾病综合征患者肾功能及炎症因子的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年08期
页码:
158-160
栏目:
药物与临床
出版日期:
2020-04-15

文章信息/Info

Title:
Effect of Low Molecular Weight Heparin Combined with Rosuvastatin and Prednisone Acetate in the Treatment of Patients with Nephrotic Syndrome
文章编号:
1006-1959（2020）08-0158-03
作者:
刘廷胜
（天津市蓟州区中医医院内科，天津 301900）
Author(s):
LIU Ting-sheng
(Department of Internal Medicine,Jizhou District Traditional Chinese Medicine Hospital,Tianjin 301900,China)
关键词:
肾病综合征; 低分子肝素; 瑞舒伐他汀; 肾功能炎症因子
Keywords:
Nephrotic syndrome; Low molecular weight heparin; Rosuvastatin; Renal function inflammatory factor
分类号:
R692.5
DOI:
10.3969/j.issn.1006-1959.2020.08.052
文献标志码:
A
摘要:
目的 探讨低分子肝素结合瑞舒伐他汀与醋酸泼尼松治疗肾病综合征患者的效果。方法 选择2018年1月~2019年1月我院收治的肾病综合征患者80例作为研究对象，根据随机数字表法分为对照组和观察组，每组40例。对照组口服瑞舒伐他汀钙片+醋酸泼尼松片治疗，观察组在对照组基础上联合低分子肝素注射液治疗，比较两组治疗前后肾功能[血浆白蛋白（ALB）、血肌酐（Scr）、尿素氮（BUN）、24 h尿蛋白定量]、炎症因子[肿瘤坏死因子-α（TNF-α）、白细胞介素-1（IL-1）、白细胞介素-6（IL-6）]及血脂水平[总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）]。结果 治疗后，观察组Scr、BUN、ALB及24 h尿蛋白定量低于对照组，差异有统计学意义（P＜0.05）；观察组IL-6、TNF-α、IL-1、TC、TG、LDL-C水平均低于对照组，HDL-C水平高于对照组，差异有统计学意义（P＜0.05）。结论 低分子肝素联合瑞舒伐他汀与醋酸泼尼松治疗肾病综合征患者效果确切，有助于改善肾功能，降低炎性因子水平及血脂水平。
Abstract:
Objective To investigate the effect of low molecular weight heparin combined with rosuvastatin and prednisone acetate in the treatment of patients with nephrotic syndrome (NS).Methods 80 patients with nephrotic syndrome admitted to our hospital from January 2018 to January 2019 were selected as the research object, and were divided into a control group and an observation group according to the random number table method, with 40 cases in each group. The control group was treated with rosuvastatin calcium tablets+prednisone acetate tablets. The observation group was treated with low-molecular-weight heparin injection on the basis of the control group to compare renal function before and after treatment [plasma albumin (ALB), blood creatinine ( Scr), urea nitrogen (BUN), 24 h urine protein quantification], inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6 )] And blood lipid levels [total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)].Results After treatment, the Scr, BUN, ALB and 24 h urine protein levels in the observation group were lower than the control group, the difference was statistically significant (P<0.05); the observation group IL-6, TNF-α, IL-1, TC, TG, LDL -C level was lower than the control group, HDL-C level was higher than the control group, the difference was statistically significant (P<0.05).Conclusion Low molecular weight heparin combined with rosuvastatin and prednisone acetate has a definite effect on the treatment of NS, which can help improve renal function and reduce the level of inflammatory factors and blood lipid levels.

参考文献/References:

[1]屠晶晶,郭旭,王帅,等.泼尼松联合知柏地黄丸治疗对肾病综合征肾功能及炎症因子水平的影响[J].中国药物与临床,2019,19(3):355-357.[2]张玥.中西医结合治疗肾病综合征临床疗效观察[J].世界中医药,2017,12(2):323-326.[3]中华医学会.《临床诊疗指南(肾脏病学分册)》[M].人民卫生出版社,2011:39-43.[4]唐杰.他克莫司联合糖皮质激素治疗肾病综合征的疗效及对炎症因子的影响[J].医学临床研究,2017,34(4):685-687.[5]白雪梅,李向东,李毅.肾炎康复片联合他克莫司治疗肾病综合征的临床研究[J].现代药物与临床,2019,34(5):1492-1495.[6]拜尔娜·那扎瓦尔，艾力克木·阿不都玩克，巴合提古丽·苏力坦.泼尼松龙联合低分子肝素治疗小儿肾病综合征的疗效及对肾功能指标的影响[J].临床和实验医学杂志,2018,17(17):1878-1880.[7]吴海樱,史菀萍.不同剂量低分子肝素联合瑞舒伐他汀治疗肾病综合征的临床疗效分析[J].检验医学与临床,2017,14(1):37-39.[8]何洋,赵小玉.低分子肝素联合强的松对小儿肾病综合征的治疗效果及对患儿肾功能、APTT、PT水平的影响分析[J].川北医学院学报,2018,33(2):268-270.[9]阳晓,黄旋,余学清.肾病综合征的新型生物学标志物研究进展[J].中华肾病研究电子杂志,2017,6(4):145-148.

相似文献/References:

[1]刘广涛,关凤军,董 晨.原发性肾病综合征患儿肾组织P-gp170蛋白和mRNA表达与临床病理及预后的关系[J].医学信息,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
　LIU Guang-tao,GUAN Feng-jun,DONG Chen.Relationship between the Expression of p-gp170 Protein and mRNA in Renal Tissue of Children with Primary Nephrotic Syndrome and Clinical Pathology and Prognosis[J].Medical Information,2018,31(08):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
[2]陈志萍.阿托伐他汀联合低分子肝素治疗短暂性脑缺血临床疗效[J].医学信息,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
　CHEN Zhi-ping.Clinical Efficacy of Atorvastatin Combined with Low Molecular Weight Heparin in the Treatment of Transient Cerebral Ischemia[J].Medical Information,2019,32(08):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
[3]王晓芳.低分子肝素治疗COPD合并Ⅱ型呼吸衰竭的临床疗效[J].医学信息,2019,32(19):155.[doi:10.3969/j.issn.1006-1959.2019.19.051]
　WANG Xiao-fang.Clinical Efficacy of Low Molecular Weight Heparin in the Treatment of COPD with Type II Respiratory Failure[J].Medical Information,2019,32(08):155.[doi:10.3969/j.issn.1006-1959.2019.19.051]
[4]沙梦晗,陈素华,亢庆玲,等.低分子肝素治疗胎儿生长受限的临床疗效分析[J].医学信息,2019,32(14):61.[doi:10.3969/j.issn.1006-1959.2019.14.020]
　SHA Meng-han,CHEN Su-hua,Kang Qing-ling,et al.Clinical Analysis of Low Molecular Weight Heparin in the Treatment of Fetal Growth Restriction[J].Medical Information,2019,32(08):61.[doi:10.3969/j.issn.1006-1959.2019.14.020]
[5]王世芳.预见性护理对肾病综合征患者并发症发生率及护理满意度的影响[J].医学信息,2020,33(01):188.[doi:10.3969/j.issn.1006-1959.2020.01.063]
　WANG Shi-fang.Effect of Predictive Nursing on the Incidence of Complications and Nursing Satisfaction in Patients with Nephrotic Syndrome[J].Medical Information,2020,33(08):188.[doi:10.3969/j.issn.1006-1959.2020.01.063]
[6]龚嘉玮,朱旭日,徐 锋,等.化瘀定痛液联合低分子肝素治疗老年粗隆间骨折围手术期肿痛的效果[J].医学信息,2020,33(03):148.[doi:10.3969/j.issn.1006-1959.2020.03.048]
　GONG Jia-wei,ZHU Xu-ri,XU Feng,et al.Effect of Huayudingtong Liquid Combined with Low-molecular-weight Heparin on Perioperative Swelling and Pain in Elderly Intertrochanteric Fractures[J].Medical Information,2020,33(08):148.[doi:10.3969/j.issn.1006-1959.2020.03.048]
[7]周浩东,哈敏文.低分子肝素对晚期非小细胞肺癌化疗疗效及预后的影响[J].医学信息,2020,33(10):161.[doi:10.3969/j.issn.1006-1959.2020.10.049]
　ZHOU Hao-dong,HA Min-wen.Effects of Low Molecular Weight Heparin on the Efficacy and Prognosis of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2020,33(08):161.[doi:10.3969/j.issn.1006-1959.2020.10.049]
[8]隋文峰,马海英.低分子肝素治疗急性肺栓塞的疗效[J].医学信息,2020,33(16):118.[doi:10.3969/j.issn.1006-1959.2020.16.036]
　SUI Wen-feng,MA Hai-ying.Efficacy of Low Molecular Weight Heparin in the Treatment of Acute Pulmonary Embolism[J].Medical Information,2020,33(08):118.[doi:10.3969/j.issn.1006-1959.2020.16.036]
[9]王艳秋.黄葵胶囊联合醋酸泼尼松治疗原发性肾病综合征的疗效[J].医学信息,2020,33(17):168.[doi:10.3969/j.issn.1006-1959.2020.17.051]
　WANG Yan-qiu.The Effect of Huangkui Capsule Combined with Prednisone Acetate in the Treatment of Primary Nephrotic Syndrome[J].Medical Information,2020,33(08):168.[doi:10.3969/j.issn.1006-1959.2020.17.051]
[10]周 琳,方界界.不同白蛋白水平的肾病综合征患者凝血功能比较[J].医学信息,2020,33(20):94.[doi:10.3969/j.issn.1006-1959.2020.20.027]
　ZHOU Lin,FANG Jie-jie.Comparison of Coagulation Function in Nephrotic Syndrome Patients with Different Albumin Levels[J].Medical Information,2020,33(08):94.[doi:10.3969/j.issn.1006-1959.2020.20.027]
[11]钱朝庆,刘 淼,王家平,等.肾病综合征合并肾静脉血栓应用阿加曲班疗效评价[J].医学信息,2018,31(21):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
　QIAN Chao-qing,LIU Miao,WANG Jia-ping,et al.Clinical Efficacy Evaluation of Argatroban in Nephrotic Syndrome with Renal Vein Thrombosis[J].Medical Information,2018,31(08):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]

更新日期/Last Update: 2020-04-15